Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma : univariate and multivariate analyses of a real-world study in Europe
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Real-world data on treatment patterns/outcomes for metastatic pancreatic cancer (mPAC) are limited. This study aims to assess real-world treatment patterns, survival outcomes, and prognostic/predictive factors in patients with mPAC.
METHODS: Retrospective, observational, chart-review involving medical oncologists and gastroenterologists from five European countries. Physicians reported information on disease and patient characteristics, diagnosis, and treatment for patients diagnosed with mPAC from January-October 2016. Outcomes included median progression-free survival (mPFS), median overall survival (mOS), and the impact of baseline performance status on survival. Univariate/multivariate regression analyses were undertaken to identify prognostic/predictive factors.
RESULTS: Three hundred four physicians and 3432 patients were included. First-line therapies included modified (m)FOLFIRINOX (28.4%), gemcitabine + nab-paclitaxel (28.0%), and gemcitabine monotherapy (23.0%). Frequent second-line therapies were gemcitabine monotherapy (25.0%), fluorouracil (5-FU) + oxaliplatin (21.8%), and gemcitabine + nab-paclitaxel (16.7%). Most frequent first- to second-line treatment sequences were gemcitabine + nab-paclitaxel followed by fluoropyrimidine combinations. Longest unadjusted estimated mOS was observed with (m)FOLFIRINOX followed by gemcitabine-based combinations (19.1 months). Multivariate analysis identified significant prognostic/predictive factors for OS and PFS including performance status and carbohydrate antigen 19-9 (CA 19-9) levels.
CONCLUSIONS: Treatment and treatment sequences were generally in accordance with guidelines at the time of the study. Identification of prognostic/predictive factors for survival may help inform the individualised management of mPAC patients in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC cancer - 23(2023), 1 vom: 18. Sept., Seite 877 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taieb, Julien [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gemcitabine |
|---|
| Anmerkungen: |
Date Completed 20.09.2023 Date Revised 13.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-023-11377-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362202869 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362202869 | ||
| 003 | DE-627 | ||
| 005 | 20231227131616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-023-11377-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM362202869 | ||
| 035 | |a (NLM)37723453 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taieb, Julien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma |b univariate and multivariate analyses of a real-world study in Europe |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a BACKGROUND: Real-world data on treatment patterns/outcomes for metastatic pancreatic cancer (mPAC) are limited. This study aims to assess real-world treatment patterns, survival outcomes, and prognostic/predictive factors in patients with mPAC | ||
| 520 | |a METHODS: Retrospective, observational, chart-review involving medical oncologists and gastroenterologists from five European countries. Physicians reported information on disease and patient characteristics, diagnosis, and treatment for patients diagnosed with mPAC from January-October 2016. Outcomes included median progression-free survival (mPFS), median overall survival (mOS), and the impact of baseline performance status on survival. Univariate/multivariate regression analyses were undertaken to identify prognostic/predictive factors | ||
| 520 | |a RESULTS: Three hundred four physicians and 3432 patients were included. First-line therapies included modified (m)FOLFIRINOX (28.4%), gemcitabine + nab-paclitaxel (28.0%), and gemcitabine monotherapy (23.0%). Frequent second-line therapies were gemcitabine monotherapy (25.0%), fluorouracil (5-FU) + oxaliplatin (21.8%), and gemcitabine + nab-paclitaxel (16.7%). Most frequent first- to second-line treatment sequences were gemcitabine + nab-paclitaxel followed by fluoropyrimidine combinations. Longest unadjusted estimated mOS was observed with (m)FOLFIRINOX followed by gemcitabine-based combinations (19.1 months). Multivariate analysis identified significant prognostic/predictive factors for OS and PFS including performance status and carbohydrate antigen 19-9 (CA 19-9) levels | ||
| 520 | |a CONCLUSIONS: Treatment and treatment sequences were generally in accordance with guidelines at the time of the study. Identification of prognostic/predictive factors for survival may help inform the individualised management of mPAC patients in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Metastatic | |
| 650 | 4 | |a Pancreatic cancer | |
| 650 | 4 | |a Prognostic factors | |
| 650 | 4 | |a Real-world data | |
| 650 | 4 | |a Survival | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 700 | 1 | |a Seufferlein, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Reni, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Palmer, Daniel H |e verfasserin |4 aut | |
| 700 | 1 | |a Bridgewater, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Cubillo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Prager, Gerald W |e verfasserin |4 aut | |
| 700 | 1 | |a Vermeire, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Hédouin-Biville, Fabienne |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Zhaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Macarulla, Teresa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 23(2023), 1 vom: 18. Sept., Seite 877 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:18 |g month:09 |g pages:877 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-023-11377-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 18 |c 09 |h 877 | ||